Abstract |
We present a 53-year-old man who underwent proximal gastrectomy for gastric gastrointestinal stromal tumor (GIST) in August 2005. Imatinib mesilate ( imatinib) 400 mg/day was started in February 2006 for left adrenal metastasis. Tumor size markedly decreased by April 2006, but medication had to be discontinued due to a pruritic rash. A distal pancreatectomy, splenectomy, and left adrenectomy were performed in August for recurrent adrenal metastases. Imatinib 200 mg/day started postoperatively was discontinued immediately due to fever and pruritus. Local recurrence with peritoneal dissemination was found in February 2007. Imatinib 100 mg/day with prednisolone (PDL) 5 mg/day was discontinued in two days due to pruritic dermatitis. Imatinib 200 mg/day with PDL 40 mg/day was restarted in April due to an increase in tumor size. Treatment continued without obvious side effects, and PDL dosage was tapered to 10 mg/day. The tumor was no longer visible on CT in May 2008, and complete response is being maintained as of August 2009.
|
Authors | Yuichiro Tsukada, Katsunori Tauchi, Masato Nakamura, Hirofumi Kishimoto, Seijiro Yoshifuku, Noriaki Otagiri, Kotaro Sasahara |
Journal | Gan to kagaku ryoho. Cancer & chemotherapy
(Gan To Kagaku Ryoho)
Vol. 37
Issue 11
Pg. 2181-4
(Nov 2010)
ISSN: 0385-0684 [Print] Japan |
PMID | 21084823
(Publication Type: Case Reports, English Abstract, Journal Article)
|
Chemical References |
- Benzamides
- Piperazines
- Pyrimidines
- Imatinib Mesylate
- Prednisolone
|
Topics |
- Benzamides
- Drug Eruptions
(etiology, prevention & control)
- Drug Therapy, Combination
- Gastrointestinal Stromal Tumors
(drug therapy)
- Humans
- Imatinib Mesylate
- Male
- Middle Aged
- Neoplasm Metastasis
- Piperazines
(administration & dosage, adverse effects)
- Prednisolone
(administration & dosage)
- Pruritus
(chemically induced, prevention & control)
- Pyrimidines
(administration & dosage, adverse effects)
- Treatment Outcome
|